ETH and University of Zurich launch new translational center
Switzerland’s ETH Zurich and the University of Zurich (UZH) are taking their long-standing partnership to a new level with a new translational research center.
The two universities are founding the Wyss Translational Center Zurich (WTZ) with funds donated by Hansjörg Wyss to the ETH Zurich Foundation. The core idea and motivation behind the initiative is to ensure that knowledge from basic and preclinical research can be applied in practice more quickly; in other words, an efficient translation into new medical therapies and innovative products.
The WTZ will initially include two technology platforms – one for regenerative medicine and the other for robotics. The center will bridge disciplinary and institutional barriers and unite researchers across various disciplines, ranging from technology and medicine through to materials science, stem cell research and robotics.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze